Advertisement

Topics

Latest "Copernicus Therapeutics" News Stories

15:00 EDT 17th October 2018 | BioPortfolio

Here are the most relevant search results for "Copernicus Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Copernicus Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Copernicus Therapeutics for you to read. Along with our medical data and news we also list Copernicus Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Copernicus Therapeutics Companies for you to search.

Showing "Copernicus Therapeutics" News Articles 1–25 of 7,700+

Extremely Relevant

M&As this week: WIRB-Copernicus, AbCellera Biologics, Apricus Biosciences

WIRB-Copernicus Group has completed the acquisition of KMR Group and Metrics Champion Consortium (MCC) for an undisclosed sum. The acquired...Read More... The post M&As this week: WIRB-Copernicus, AbCellera Biologics, Apricus Biosciences appeared first on Drug Development Technology.


Relevant

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

WIRB-Copernicus Group clinical services division acquires ACI Clinical

WCG Clinical Services Division expands portfolio to include specialist in endpoint adjudication and data monitoring safety committees


Copernicus Award 2018: Outstanding German-Polish cooperation in cardiology

(Deutsche Forschungsgemeinschaft) Cardiologists from Berlin and Wrocaw to receive the award from the DFG and the Foundation for Polish Science / Award ceremony to take place on October 25 in Berlin.

WCG Clinical Services Division expands portfolio through acquisition of ACI Clinical

Clinical services organisation, WIRB-Copernicus Group (WCG) Clinical Services Division, has expanded its portfolio through the acquisition of a provider of Endpoint Adjudication and Data Monitoring Safety Committees.

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12.39. The stock Read more...

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin appeared first on Drug Development Technology.

Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, ...

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific The post HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics appeared first on Pharma Business review.

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics appeared first on Drug Development Technology.

Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics

Celsius Therapeutics has raised $65m in a series A financing round led by Third Rock Ventures with participation from Google Ventures,...Read More... The post Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics appeared first on Drug Development Technology.

Alexion to Acquire Wilson Therapeutics and its Rare Liver Disorder Drug

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Wilson Therapeutics AB (publ) announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. Wilson Therapeutics is a biopharmaceutical com...

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Probably Relevant

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.

Dermatology start-up Hoth Therapeutics files for IPO

Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for ...

Nabriva Acquires Zavante Therapeutics and its Late-Stage Antibiotic

Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.

Novelion Therapeutics Inc.: Novelion Therapeutics Supports World Lipodystrophy Day

VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals ...

e-Therapeutics and C4XD research Parkinson's drugs

UK biotech e-Therapeutics is to work with genomics firm C4X Discovery to develop new therapies for Parkinson’s disease. e-Therapeutics has been under the leadership of CEO Ray Barlow for more than a year, who has been refocusing the biotech’s rese...

AdoRx raises $10m funding to discover new cancer therapeutics

UK-based AdoRx Therapeutics, which is focused on discovering new cancer therapeutics, has secured an initial $10m investment round financed by Epidarex Capital and CRT Pioneer Fund (CPF).

SMi Group announces the 10th Annual RNA Therapeutics Conference

20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board...    

Carisma Therapeutics to expand its technology platform towards clinical development

Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately─held biotechnology company focused on the development of macrophage─based immunotherapeutics, announced the close of a $53 million Series A

Summit Therapeutics plc: Summit Therapeutics Files US Annual Report on Form 20F

Summit Therapeutics plc ('Summit', or the 'Company')Summit Therapeutics Files US Annual Report on Form 20-FOxford, UK, and Cambridge, MA, US, 13 April 2018 - Summit Therapeutics plc (AIM: SUMM, NA...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks